Medicine and Dentistry
Systemic Lupus Erythematosus
100%
Patient
98%
Antiphospholipid Syndrome
88%
Therapeutic Procedure
37%
Inpatient
34%
Pregnancy
32%
Antiphospholipid Antibody
30%
Thrombosis
21%
Association
19%
Diagnosis
18%
Antibody
18%
Woman
17%
Disease
16%
Combination Therapy
15%
Lupus Nephritis
15%
Autoantibody
14%
Analysis
12%
Syndrome
12%
Lupus Anticoagulant
11%
Rituximab
9%
Cohort Analysis
9%
Disease Activity
9%
Autoimmune Disease
9%
Pathogenesis
9%
Morbidity
8%
Prevalence
8%
Acetylsalicylic Acid
7%
Obstetrics
7%
Physician
7%
Apoplexy
7%
Systematic Review
7%
Low Drug Dose
6%
Assessment
6%
Adult
6%
Atherosclerosis
6%
Proteinuria
6%
Follow up
6%
Warfarin
6%
Evaluation Study
6%
Chemotherapeutic Agent
6%
Drug
6%
Beta2 Glycoprotein 1
6%
Mortality
6%
Age
5%
Cardiolipin Antibody
5%
Anticoagulation
5%
Hypertension
5%
Rheumatology
5%
Estrogen
5%
B Cell
5%
Immunology and Microbiology
Systemic Lupus Erythematosus
76%
Antiphospholipid Syndrome
70%
Phospholipid Antibody
38%
Lupus Erythematosus
32%
Monospecific Antibody
31%
Pregnancy
25%
Autoantibodies
21%
Association
15%
Lupus Anticoagulant
12%
Cardiolipin Antibody
12%
Nephritis
9%
Prevalence
8%
Prothrombin Antibody
6%
Time
6%
Atherosclerosis
6%
Development
6%
Morbidity
5%
Immunoglobulin M
5%
Gene
5%
Rituximab
5%
Age
5%
ELISA
5%
Immunoglobulin A
5%
Pharmacology, Toxicology and Pharmaceutical Science
Antiphospholipid Syndrome
52%
Systemic Lupus Erythematosus
39%
Antiphospholipid Antibody
13%
Diseases
12%
Thrombosis
11%
Antibody
8%
Warfarin
7%
Lupus Vulgaris
6%
Beta2 Glycoprotein 1
6%
Rituximab
6%
Syndrome
6%
Morbidity
6%
Autoimmune Disease
5%
Drug
5%
Cardiolipin Antibody
5%
Anticoagulant Agent
5%
Autoantibody
5%